If vaginal dryness is the main change after menopause, testosterone is usually the wrong first question.
The better first question is: is this genitourinary syndrome of menopause, hypoactive sexual desire disorder, both, or something that needs evaluation before any sexual-medicine treatment? Genitourinary syndrome of menopause can include dryness, burning, irritation, painful sex, urinary urgency, pain with urination, and recurrent urinary tract infections. The 2025 AUA/SUFU/AUGS guideline says clinicians diagnose genitourinary syndrome of menopause from symptoms, with or without related physical findings, after ruling out other causes or co-occurring conditions. It also says local low-dose vaginal estrogen has the most robust evidence base among genitourinary syndrome of menopause treatments. [1]
Testosterone has a different evidence category. The global consensus statement says the only evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder in postmenopausal women after assessment. [6] The International Society for the Study of Women's Sexual Health guideline recommends a biopsychosocial assessment, baseline testosterone for monitoring rather than diagnosis, avoidance of supraphysiologic levels, and follow-up for androgen-type side effects. [7]
That distinction protects the reader from a common mistake: using a desire treatment to answer a tissue, pain, urinary, infection, or bleeding question.
The first split is vaginal and urinary symptoms versus low desire disorder
Dryness and desire can overlap, but they are not the same diagnosis. A woman may have low desire because sex hurts. Another may have persistent low desire with distress even after pain and dryness are controlled. Those are different decisions.
| What you are describing | Better first category | Why it matters |
|---|---|---|
| Vaginal dryness, burning, irritation, or tissue fragility | genitourinary syndrome of menopause evaluation | genitourinary syndrome of menopause guidance directly covers these symptoms and asks clinicians to rule out other causes. [1] |
| Pain with sex that feels related to dryness or tightness | genitourinary syndrome of menopause and pelvic-pain review | Treating pain first can change desire without making testosterone the first move. [1] [2] |
| Recurrent urinary urgency, burning with urination, or recurrent UTIs after menopause | genitourinary syndrome of menopause plus urinary evaluation | genitourinary syndrome of menopause can include urinary symptoms, but infection and bladder conditions may coexist. [1] |
| Persistent low desire with distress after pain, genitourinary syndrome of menopause, sleep, mood, medicines, and relationship factors are reviewed | hypoactive sexual desire disorder assessment | This is the category where systemic testosterone may be discussed. [6] [7] |
| Bleeding after menopause, new pelvic pain, discharge, sores, fever, or infection symptoms | Evaluation before sexual-medicine treatment | These findings can change the diagnosis and should not be masked by a hormone trial. [3] [4] [5] [9] |
The practical takeaway is simple: a low-libido visit that starts with painful dryness should not jump straight to testosterone. It should first clarify whether pain, tissue change, infection, medication effects, mood, sleep, or relationship context is driving the low desire.
What vaginal and urinary symptoms care usually covers before testosterone
Genitourinary syndrome of menopause treatment is not one product. It is a route decision: nonhormonal symptom care, local estrogen, vaginal dehydroepiandrosterone, an oral estrogen agonist/antagonist, pelvic-floor or pain evaluation, or a different workup if symptoms do not fit genitourinary syndrome of menopause.
The Menopause Society 2020 position statement estimated genitourinary syndrome of menopause affects approximately 27% to 84% of postmenopausal women and notes it is underdiagnosed and undertreated. It lists lubricants and moisturizers, vaginal estrogens, vaginal dehydroepiandrosterone, systemic hormone therapy, and ospemifene as options depending on symptom severity, safety, and preference. It also says nonhormone therapies can provide sufficient relief for most women with mild symptoms, while low-dose vaginal estrogens, vaginal dehydroepiandrosterone, systemic estrogen therapy, and ospemifene are effective for moderate to severe genitourinary syndrome of menopause. [2]
| genitourinary syndrome of menopause option | What it is usually trying to solve | Important boundary |
|---|---|---|
| Lubricants | Friction during sex | Symptom help during sex; not a tissue-reversal claim. [2] |
| Moisturizers | Baseline dryness and irritation | Often reasonable for mild symptoms; persistent pain needs reassessment. [2] |
| Low-dose vaginal estrogen | Moderate to severe genitourinary syndrome of menopause symptoms, depending on history | The 2025 genitourinary syndrome of menopause guideline describes this as the most robust evidence base, but history and contraindications still matter. [1] |
| Intravaginal prasterone | Moderate to severe dyspareunia due to vulvar and vaginal atrophy from menopause | DailyMed lists this indication and also lists undiagnosed abnormal genital bleeding as a contraindication. [3] |
| Ospemifene | Moderate to severe dyspareunia or vaginal dryness due to vulvar and vaginal atrophy from menopause | DailyMed lists boxed warnings and contraindications, including undiagnosed abnormal genital bleeding and thromboembolic disease history. [4] |
| Pelvic-floor, dermatology, infection, or urinary evaluation | Pain, burning, sores, discharge, recurrent urinary symptoms, or symptoms not explained by genitourinary syndrome of menopause | A different diagnosis can change the whole plan. [1] |
This is why "testosterone for dryness" is too imprecise. The genitourinary syndrome of menopause category has its own evidence, products, contraindications, and red flags.
Prasterone and ospemifene show why route matters
Intravaginal prasterone is a local vaginal dehydroepiandrosterone product. Its current DailyMed label says it is indicated for moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause. [3] In pooled randomized data from three studies, 436 women used prasterone and 260 used placebo. Painful-sex severity improved 0.46 units more than placebo, and vaginal dryness improved 0.31 units more than placebo over 12 weeks. [8]
Ospemifene is different: it is an oral estrogen agonist/antagonist. The current DailyMed label says it is indicated for moderate to severe dyspareunia and moderate to severe vaginal dryness, both symptoms of vulvar and vaginal atrophy due to menopause. It also carries boxed-warning and contraindication language that makes history-taking important before use. [4]
| Option | Route | Label-backed genitourinary syndrome of menopause use | Safety questions that can change fit |
|---|---|---|---|
| Intravaginal prasterone | Vaginal insert | Moderate to severe dyspareunia due to menopause-related vulvar and vaginal atrophy. [3] | Undiagnosed persistent or recurrent genital bleeding; current or past breast cancer history. [3] |
| Ospemifene | Oral tablet | Moderate to severe dyspareunia or vaginal dryness due to menopause-related vulvar and vaginal atrophy. [4] | Uterus/endometrial risk, abnormal bleeding, deep vein thrombosis or pulmonary embolism history, stroke or heart attack history, pregnancy possibility. [4] |
| Estradiol vaginal cream | Vaginal estrogen cream | Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. [5] | Undiagnosed abnormal genital bleeding, breast cancer history, thromboembolic history, liver disease, and systemic estrogen warnings. [5] |
These are not interchangeable with testosterone. They target genitourinary syndrome of menopause symptoms more directly, while testosterone targets a narrower sexual-desire diagnosis.
Where testosterone fits, and where it does not
The testosterone evidence base is strongest for postmenopausal women with hypoactive sexual desire disorder after careful assessment. The global consensus statement keeps the claim narrow: testosterone therapy's only evidence-based indication for women is hypoactive sexual desire disorder in postmenopausal women. [6]
International Society for the Study of Women's Sexual Health adds the practical guardrails. Systemic transdermal testosterone may be considered for women with hypoactive sexual desire disorder that is not primarily related to modifiable factors or comorbidities such as relationship or mental-health problems. A total testosterone level should not be used to diagnose hypoactive sexual desire disorder; it is used as a baseline for monitoring. Patients should be monitored for signs of androgen excess, and testosterone levels should be kept in the physiologic premenopausal range. International Society for the Study of Women's Sexual Health also states long-term safety has not been established and that compounded products cannot be recommended because of lack of efficacy and safety data. [7]
| Question | Testosterone is more plausible when | Testosterone is a poor first fit when |
|---|---|---|
| What is the main symptom? | Persistent low desire with distress. [6] [7] | Dryness, burning, irritation, urinary symptoms, or pain from dry tissue is the main complaint. [1] [2] |
| Has genitourinary syndrome of menopause been addressed? | genitourinary syndrome of menopause, pain, and infection concerns have been evaluated or treated, but distressing low desire persists. | Sex hurts and the pain has not been evaluated or treated. |
| Are modifiable drivers present? | Medicines, sleep, depression, anxiety, relationship stress, hot flashes, and pain have been reviewed. [7] | Low desire appears primarily tied to a modifiable driver that has not been addressed. [7] |
| Is monitoring possible? | Baseline level, follow-up level, side-effect review, and dose boundaries are in place. [7] | The plan is a vague "boost testosterone" approach without monitoring. |
| Is the product appropriate? | A clinician is using a dose strategy intended to avoid high levels. [7] | The plan relies on pellets, high-dose products, or compounded formulas without clear safety and efficacy support. [7] |
This is the useful pivot for the clinical visit: not "Can I get testosterone?" but "Which symptom category am I actually in, and what would make testosterone appropriate or inappropriate?"
Who this fits, and who should not use a testosterone-first plan
This page fits a postmenopausal woman whose dryness, painful sex, urinary symptoms, or low desire has been collapsed into one hormone question. It is especially useful when she has been told that "low testosterone" explains everything, but her main complaint is dryness, burning, pain, recurrent urinary symptoms, or fear of painful sex.
It is also useful when both problems may be true. A woman can have genitourinary syndrome of menopause and hypoactive sexual desire disorder. In that case, the plan should separate the sequence: treat or evaluate genitourinary syndrome of menopause and pain first, then reassess whether low desire with distress remains.
A testosterone-first plan is a poor fit when bleeding after menopause, new pelvic pain, discharge, sores, fever, suspected infection, unexplained urinary symptoms, or a history of hormone-sensitive cancer or thromboembolic disease has not been reviewed. It is also a poor fit when the plan depends on a single testosterone blood test as the diagnosis. International Society for the Study of Women's Sexual Health is explicit that the blood level is not the diagnosis; it is part of baseline and monitoring. [7]
Red flags that should change the plan
Red flags do not mean the worst diagnosis is likely. They mean the treatment sequence changes. Painful sex plus bleeding is not the same decision as painful sex from dryness alone.
| Red flag | Why it changes the next step |
|---|---|
| Bleeding after 12 or more months without a period | The American College of Obstetricians and Gynecologists 2026 update describes postmenopausal bleeding as bleeding presumed from the uterus 12 or more months after the final menstrual period and emphasizes prompt evaluation because approximately 90% of patients diagnosed with endometrial cancer have postmenopausal bleeding. [9] |
| Persistent or recurrent abnormal genital bleeding before prasterone, ospemifene, or vaginal estrogen | Current DailyMed labels for prasterone, ospemifene, and Estrace all flag undiagnosed abnormal genital bleeding as a contraindication or reason for evaluation. [3] [4] [5] |
| New pelvic pain, fever, discharge, sores, or suspected infection | genitourinary syndrome of menopause may coexist with infection, dermatologic disease, pelvic-floor pain, or another gynecologic condition. [1] |
| Pain is severe, one-sided, worsening, or not clearly related to dryness | That pattern needs evaluation rather than a default hormone or supplement answer. |
| A desire treatment is being offered without reviewing pain, medicines, mood, sleep, relationship context, or genitourinary syndrome of menopause | International Society for the Study of Women's Sexual Health frames testosterone use around biopsychosocial assessment, not a blood-test-only shortcut. [7] |
What to ask your clinician
- Is my main problem genitourinary syndrome of menopause, hypoactive sexual desire disorder, pelvic-floor pain, infection, a skin condition, medication effect, mood, sleep, relationship context, or more than one of these?
- If sex hurts, what needs to be evaluated before we call this low desire?
- Do moisturizers, lubricants, low-dose vaginal estrogen, prasterone, ospemifene, pelvic-floor therapy, or infection testing fit my symptoms better than systemic testosterone?
- If testosterone is being considered, what diagnosis supports it, what dose route is being used, what baseline level is being recorded, and when will levels and side effects be checked?
- What history would make a genitourinary syndrome of menopause medication or testosterone plan inappropriate for me?
- What symptoms mean I should pause treatment and get checked, especially bleeding after menopause, new pelvic pain, discharge, sores, fever, or worsening urinary symptoms?
Bottom line
When the main complaint is vaginal dryness, burning, urinary symptoms, or painful sex from dry tissue, start with genitourinary syndrome of menopause. When the main complaint is persistent low desire with distress after genitourinary syndrome of menopause, pain, mood, sleep, medicine, and relationship factors have been reviewed, testosterone may enter the discussion.
The durable decision is not "testosterone for vaginal dryness." It is symptom-category triage: genitourinary syndrome of menopause care, hypoactive sexual desire disorder assessment, red-flag evaluation, or more than one track.
Related reading:
- Vaginal Estrogen After Menopause.
- Prasterone After Menopause.
- Ospemifene After Menopause.
- dehydroepiandrosterone vs Testosterone After Menopause.
- Testosterone Blood Tests After Menopause.
- Testosterone Monitoring After Menopause.
References
[1] Kaufman MR, Ackerman AL, Amin KA, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 2025;214(3):242-250. doi:10.1097/ju.0000000000004589 https://pubmed.ncbi.nlm.nih.gov/40298120/
[2] The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi:10.1097/gme.0000000000001609 https://pubmed.ncbi.nlm.nih.gov/32852449/
[3] DailyMed. INTRAROSA (prasterone) insert, current label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ada639d4-bac0-2ad0-e053-2a95a90afce7
[4] DailyMed. OSPHENA (ospemifene) tablet, current label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9accbcc9-78ee-4f84-9b7e-704f2ab1c413
[5] DailyMed. ESTRACE (estradiol) vaginal cream, current label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfc41fcd-c5ba-4b25-b647-cf04d3988b3e
[6] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[7] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009 https://pubmed.ncbi.nlm.nih.gov/33814355/
[8] Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017;24(11):1246-1256. doi:10.1097/gme.0000000000000910 https://pubmed.ncbi.nlm.nih.gov/28640161/
[9] American College of Obstetricians and Gynecologists. ACOG publishes updated guidance on evaluation of postmenopausal bleeding. https://www.acog.org/news/news-releases/2026/04/acog-publishes-updated-guidance-evaluation-postmenopausal-bleeding